Royal Bank Of Canada Infla Rx N.V. Transaction History

Royal Bank Of Canada

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.05 - $6.1 $293 - $872	143 Added 19.07%	893 $3,000
Q2 2022 Aug 15, 2022	BUY	$0.78 - $1.9 $585 - $1,425	750 New	750 $1,000
Q4 2021 Feb 14, 2022	SELL	$2.35 - $5.58 $1,823 - $4,330	-776 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.25 - $3.03 $1,746 - $2,351	776 New	776 $2,000

13.8M

12.9K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $72.5M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.